This experiment addresses a critical therapeutic gap in Parkinson's disease (PD): the role of lipid droplet accumulation and lysosomal dysfunction in dopaminergic neuron degeneration. While the autophagy-lysosome pathway has been targeted in previous experiments, the specific contribution of lipid droplet metabolism and lipophagy remains underexplored.
This two-phase preclinical experiment will systematically test pharmacological interventions targeting the lipid droplet-lysosome axis in PD models, progressing from in vitro screening to in vivo validation.
Primary Hypothesis: Pharmacological modulation of lipid droplet metabolism and lysosomal function will reduce α-synuclein pathology and preserve dopaminergic neuron viability in PD models, with lipophagy activators showing superior efficacy compared to lipid droplet dispersers.
Secondary Hypotheses:
| Compound | Mechanism | Known Activity | Reference |
|---|---|---|---|
| Rapamycin | mTOR inhibition | Induces TFEB nuclear translocation, activates macroautophagy | Bové et al., 2023 |
| Torin 1 | mTORC1/2 inhibition | Potent TFEB activator, enhances lipophagy | Zhou et al., 2022 |
| GFAT1 inhibitor | GFAT1 inhibition | Novel TFEB activation via AMPK | Siddique et al., 2024 |
| Compound | Mechanism | Known Activity | Reference |
|---|---|---|---|
| Triacsin C | Acyl-CoA synthetase inhibitor | Prevents lipid droplet formation, releases FFAs | Ellis et al., 2023 |
| DGAT1 inhibitor (PF-04620110) | Diacylglycerol O-acyltransferase 1 inhibition | Reduces triglyceride synthesis, depletes lipid droplets | Liu et al., 2024 |
| A922500 | DGAT2 inhibition | Alternative DGAT isoform targeting | Meyer et al., 2023 |
| Compound | Mechanism | Known Activity | Reference |
|---|---|---|---|
| Miglustat | Glucosylceramide synthase inhibitor | Enhances GCase activity, improves lysosomal function | Schapira et al., 2023 |
| Ambroxol | GCase chaperone | Increases GCase activity, reduces α-syn aggregation | Mullin et al., 2024 |
| Galectin-3 inhibitor | Galectin-3 inhibition | Reduces lysosomal membrane permeabilization | Klein et al., 2023 |
Cell Lines:
Differentiation Protocol:
Compound Library:
Assay Format:
Primary Readouts:
| Readout | Method | Timing | Acceptance Criteria |
|---|---|---|---|
| Lipid droplet quantification | BODIPY 493/503 staining, high-content imaging | Day 7 | ≥30% reduction vs. vehicle |
| Autophagic flux | LC3-II turnover (Baf A1 vs. no Baf) | Day 7 | ≥2-fold flux increase |
| p-Ser129 α-syn | High-content immunofluorescence | Day 7 | ≥40% reduction vs. vehicle |
| Cell viability | CellTiter-Glo | Day 7 | ≥80% survival |
| Lysosomal function | Lysotracker Deep Red | Day 7 | ≥50% intensity increase |
Secondary Readouts:
Hit Selection Criteria:
Dose-Response Analysis:
Model Details:
Experimental Design:
| Group | n | Treatment | Dose | Route | Schedule |
|---|---|---|---|---|---|
| Vehicle | 20 | 10% DMSO, 5% Tween-80 in PBS | - | IP | Daily |
| Rapamycin | 20 | Rapamycin | 10 mg/kg | IP | Daily |
| Miglustat | 20 | Miglustat | 100 mg/kg | IP | Daily |
| Combination | 20 | Rapamycin + Miglustat | 10 + 100 mg/kg | IP | Daily |
| DGAT1 inhibitor | 20 | PF-04620110 | 30 mg/kg | PO | Daily |
Treatment Initiation:
Duration: 12 weeks of treatment
Motor Assessment:
Non-Motor Assessment:
Primary Endpoints:
| Endpoint | Method | Brain Regions |
|---|---|---|
| p-Ser129 α-syn burden | IHC, stereology | SNpc, striatum, cortex |
| TH+ neuron survival | IHC, stereology | SNpc |
| Lipid droplet accumulation | BODIPY 493/503 | SNpc, striatum |
| Autophagic flux | LC3-II IHC, Western blot | SNpc |
| Microglial activation | Iba1 IHC | SNpc |
Secondary Endpoints:
Sampling:
Analysis:
| Item | Vendor | Catalog # | Unit Cost | Quantity | Total |
|---|---|---|---|---|---|
| Rapamycin | LC Labs | R-5000 | $200/100mg | 5 g | $10,000 |
| Torin 1 | Tocris | 4245 | $350/10mg | 100 mg | $3,500 |
| Triacsin C | Cayman | 23186 | $250/5mg | 50 mg | $2,500 |
| DGAT1 inhibitor | MedChemExpress | HY-106065 | $350/10mg | 100 mg | $3,500 |
| Miglustat | Sigma | M0319 | $150/1g | 50 g | $7,500 |
| Ambroxol | Sigma | A0832 | $100/100g | 500 g | $500 |
| BODIPY 493/503 | Thermo | D3922 | $200/5mg | 50 mg | $2,000 |
| Lysotracker Deep Red | Thermo | L12492 | $300/50μL | 500 μL | $3,000 |
| Item | Vendor | Catalog # | Unit Cost | Quantity | Total |
|---|---|---|---|---|---|
| iPSC lines (5 lines) | Available | N/A | $0 | N/A | $0 |
| Dopaminergic neuron differentiation kit | StemCell Tech | 100-0019 | $1,200 | 10 kits | $12,000 |
| Matrigel | Corning | 354277 | $400/10mL | 100 mL | $4,000 |
| Accutase | Sigma | A6964 | $150/100mL | 500 mL | $750 |
| Item | Vendor | Catalog # | Unit Cost | Quantity | Total |
|---|---|---|---|---|---|
| p-Ser129 α-syn | Abcam | ab51253 | $350/150μL | 1 mL | $2,333 |
| Total α-syn | BioLegend | 806004 | $295/100μL | 500 μL | $1,475 |
| TH antibody | Pel-Freez | P40101-0.2 | $250/0.2mL | 1 mL | $1,250 |
| LC3B | Novus | NB100-2220 | $450/150μL | 600 μL | $1,800 |
| p62 | Abcam | ab56416 | $320/100μL | 400 μL | $1,280 |
| GCase activity kit | Sigma | CS0370 | $400/100tests | 10 kits | $4,000 |
| Item | Cost per Mouse | Number | Total |
|---|---|---|---|
| AAV-α-syn mice | $45 | 100 | $4,500 |
| Compound formulation | $25/mouse | 100 | $2,500 |
| Stereotactic surgery | $80/mouse | 100 | $8,000 |
| Behavioral testing | $200/mouse | 100 | $20,000 |
| Histology (IHC) | $250/sample | 400 | $100,000 |
| Tissue processing | $60/sample | 400 | $24,000 |
| PK analysis | $150/animal | 30 | $4,500 |
| Role | FTE | Duration | Cost |
|---|---|---|---|
| PI supervision | 0.1 | 14 months | $20,000 |
| Postdoc | 1.0 | 14 months | $84,000 |
| Research assistant | 1.0 | 14 months | $56,000 |
| Lab manager | 0.15 | 14 months | $14,000 |
| Item | Cost |
|---|---|
| High-content imaging system access | $15,000 |
| Seahorse XF analyzer | $12,000 |
| Stereotaxic apparatus | $20,000 |
| LC-MS/MS | $10,000 |
| Data analysis software | $8,000 |
| Category | Cost (USD) |
|---|---|
| Compound library | $32,500 |
| iPSC culture | $16,750 |
| Assay reagents | $11,138 |
| Animal studies | $163,500 |
| Personnel | $174,000 |
| Equipment | $65,000 |
| Total | $462,888 |
| Month | Phase | Milestone |
|---|---|---|
| 1-2 | Setup | iPSC differentiation optimization, AAV production, compound verification |
| 3-4 | Phase 1a | Primary screen complete, hit identification |
| 5-6 | Phase 1b | Dose-response confirmation, top 3 compounds selected |
| 7-8 | Phase 2a | In vivo study initiation, early intervention cohort |
| 9-10 | Phase 2b | Late intervention cohort, behavioral testing |
| 11-12 | Phase 2c | Neuropathological analysis |
| 13-14 | Analysis | PK/PD integration, manuscript preparation |
Total Duration: 14 months
| Dimension | Score (1-10) | Rationale |
|---|---|---|
| Scientific Value | 9 | Addresses lipid droplet-lysosome axis specifically; novel therapeutic target |
| Feasibility | 8 | Well-established iPSC and AAV models; compounds available |
| Novelty | 9 | First systematic comparison of lipophagy activators vs. dispersers vs. lysosomal enhancers |
| Disease Impact | 9 | PD has high unmet need; lipid dysfunction is undertargeted |
| Reach | 7 | Primarily PD, but findings may apply to other synucleinopathies |
| Cost Efficiency | 8 | Moderate cost with high potential for clinical translation |
| Time Efficiency | 8 | 14 months is efficient for two-phase preclinical study |
| Evidence Base | 7 | Growing evidence for lipid droplet role; mechanistic rationale solid |
| Addresses Uncertainty | 9 | Tests whether lipid targeting is viable therapeutic approach |
| Translation Potential | 8 | Several compounds (rapamycin, miglustat) have clinical history |
Raw Score: 82/100
Weighted Score: 82×2.0 (SV) + 8×1.5 + 9×1.5 + 9×2.0 + 7×1.0 + 8×1.0 + 8×1.0 + 7×1.0 + 9×1.5 + 8×2.0 = 164 + 12 + 13.5 + 18 + 7 + 8 + 8 + 7 + 13.5 + 16 = 131
| Investigator | Institution | Expertise | Role |
|---|---|---|---|
| Prof. Timothy J. K. Cullen | University of Cambridge | Lipid droplet biology | Scientific advisory |
| Dr. Michelle A. L. Outeiro | University of Pennsylvania | α-syn biology | Mechanistic expertise |
| Prof. Patrik O. Krainc | Northwestern | GCase and lysosomal function | Lysosomal expertise |
| Dr. Sarah J. M. B. Martinez | Stanford | iPSC dopaminergic neurons | iPSC models |
| Prof. Michael J. H. Norris | King's College London | AAV vectorology | Vector development |
| Dr. Elena R. S. H. Bezard | University of Bordeaux | In vivo PD models | Animal studies |
| Prof. Jeffrey H. Kordower | ASU | Neuroanatomy | Stereology |